Mauritius: Remdesivir Not Used in Mauritius for Treatment of Covid-19

press release

The Minister of Health and Wellness, Dr Kailesh Jagutpal, stated, at the National Assembly, yesterday, that Remdesivir is not used in Mauritius for the treatment of COVID-19.

The Minister underlined that the efficacy to treat SARS-CoV-2 of Remdesivir, which is a broad-spectrum antiviral medication usually prescribed for the treatment of patients with Ebola and was used in treating COVID-19, is uncertain. He recalled that the World Health Organisation (WHO) launched a study on the effectiveness of Remdesivir last year.

A Committee of Experts from the Organisation, thus, analysed the results of four clinical trials on more than 7,000 patients hospitalised for COVID-19, which was published in the medical journal BMJ (British Medical Journal). They concluded that there was not enough evidence on the effectiveness of Remdesivir on COVID-19 patients.

In addition, said Dr Jagutpal, scientists highlight the possibility of having significant side effects from the use of Remdesivir, notwithstanding the relatively large cost and logistical implications of an intravenous medication. The Minister pointed out that on 20 November 2020, the WHO advised against the use of this antiviral medication as there was no evidence that Remdesivir improved the survival of patients or prevented them from being placed under mechanical ventilation.

More From: Government of Mauritius

Don't Miss

AllAfrica publishes around 800 reports a day from more than 130 news organizations and over 500 other institutions and individuals, representing a diversity of positions on every topic. We publish news and views ranging from vigorous opponents of governments to government publications and spokespersons. Publishers named above each report are responsible for their own content, which AllAfrica does not have the legal right to edit or correct.

Articles and commentaries that identify allAfrica.com as the publisher are produced or commissioned by AllAfrica. To address comments or complaints, please Contact us.